JX2105
/ Zhejiang Jingxin Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 05, 2024
A Randomized, Double-blind, Placebo-controlled Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JX2105 in Healthy Chinese Subjects
(clinicaltrials.gov)
- P1 | N=52 | Enrolling by invitation | Sponsor: Zhejiang Jingxin Pharmaceutical Co., Ltd.
New P1 trial • CNS Disorders • Movement Disorders • Parkinson's Disease
1 to 1
Of
1
Go to page
1